Drug Detail

Information about NeoBOMB1

Generic Name
NeoBOMB1
IND
68Ga-NeoBOMB1
Brand Name (US)
Manufacturer
Advanced Accelerator Aplications
Drug Type
Antagonist bombesin analog
Delivery
Intravenous
Approval Status
Phase 1
Indications
Overall Strategy
GIST Tumor Based
Strategy
Radio labeled tracer
Drug Category
GRPR Antagonst

Radiotracer for imaging and therapy of GRPR-expressing tumors.

Gastrin Releasing Peptide Receptors (GRPR)

177Lu-NEOBOMB1 and 68Ga-NEOBOM1. NeoBOMB1 is a unique new generation antagonist bombesin analogue targeting GRPR-expressing malignancies. Our plan is to radiolabel NeoBOMB1 to develop a theragnostic pair: 177Lu-NeoBOMB1 for treatment and a 68Ga-NeoBOMB1 for diagnosis. AAA has signed an exclusive license agreement with Erasmus University Medical Center (UMC) and Demokritos National Center for Scientific Research to develop NeoBOMB1. AAA is currently planning three clinical studies in different indications including gastrointestinal stromal tumors, prostate cancer and breast cancer.